David Epstein has more than 25 years of extensive drug development, deal making, commercialization and leadership experience on a global scale.

Even though we speak the same language, the U.S. and EU are fundamentally different in terms of culture and operating environments. This also extends to the board room and European life science CEOs must factor in these differences early on as they design their overall strategy for their U.S. market entry.

David Epstein is executive partner at Flagship Pioneering, chairman of Axcella Health, chairman of Rubius Therapeutics and chairman of Evelo Biosciences.  David is also a board member at Tarus Therapeutics and Valo Health.